ES2570973T3 - Productos y métodos para la estimulación de una respuesta inmunitaria - Google Patents

Productos y métodos para la estimulación de una respuesta inmunitaria

Info

Publication number
ES2570973T3
ES2570973T3 ES13189439T ES13189439T ES2570973T3 ES 2570973 T3 ES2570973 T3 ES 2570973T3 ES 13189439 T ES13189439 T ES 13189439T ES 13189439 T ES13189439 T ES 13189439T ES 2570973 T3 ES2570973 T3 ES 2570973T3
Authority
ES
Spain
Prior art keywords
immune response
lymphocyte
antigen
stimulating
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13189439T
Other languages
English (en)
Spanish (es)
Inventor
Facundo Batista
Julia Eckl-Dorna
Patricia Barral
Vincenzo Cerundolo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ES2570973T3 publication Critical patent/ES2570973T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES13189439T 2008-05-02 2009-05-05 Productos y métodos para la estimulación de una respuesta inmunitaria Active ES2570973T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4981408P 2008-05-02 2008-05-02

Publications (1)

Publication Number Publication Date
ES2570973T3 true ES2570973T3 (es) 2016-05-23

Family

ID=40888253

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13189439T Active ES2570973T3 (es) 2008-05-02 2009-05-05 Productos y métodos para la estimulación de una respuesta inmunitaria

Country Status (8)

Country Link
US (1) US20110280930A1 (https=)
EP (3) EP2288381A2 (https=)
JP (3) JP5721620B2 (https=)
CN (1) CN102170903B (https=)
AU (1) AU2009241645B2 (https=)
CA (1) CA2723226A1 (https=)
ES (1) ES2570973T3 (https=)
WO (1) WO2009133378A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721620B2 (ja) * 2008-05-02 2015-05-20 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 免疫応答を刺激するための作製物および方法
US20140050780A1 (en) 2010-12-23 2014-02-20 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CN103857387B (zh) 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
TW201442739A (zh) * 2013-02-27 2014-11-16 Riken 過敏疾病治療藥
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) * 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
WO2015143295A2 (en) 2014-03-20 2015-09-24 The Regents Of The University Of California Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
AU2015269412B2 (en) * 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016164705A1 (en) * 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CN107530285B (zh) 2015-04-29 2021-07-27 加利福尼亚大学董事会 使用纳米粒子解毒
JP2018516996A (ja) * 2015-06-10 2018-06-28 ウニヴェルズィテート・デ・ザールラントＵｎｉｖｅｒｓｉｔａｅｔ Ｄｅｓ Ｓａａｒｌａｎｄｅｓ Ｂ細胞悪性腫瘍を処置するための手段および方法
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017211314A1 (en) 2016-06-08 2017-12-14 Kei International Limited Method for detecting presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen
NL2017204B1 (en) * 2016-06-08 2017-12-18 Kei International Ltd Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
AU2017313806B2 (en) * 2016-08-17 2023-07-20 Orbis Health Solutions Llc Tumor-targeting bead vectors and methods of using the same
WO2019032862A1 (en) * 2017-08-10 2019-02-14 Dana-Farber Cancer Institute, Inc. CELLS EXPRESSING LMP1 AND METHODS OF USE
NL2021443B1 (en) 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3650466A1 (en) * 2018-11-12 2020-05-13 Consejo Superior De Investigaciones Científicas In vitro production of high affinity monoclonal antibodies
CN111229023B (zh) * 2018-11-29 2022-01-28 内蒙古东盛硅藻土科技创新产业园有限公司 一种化学降解添加剂
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
CN112300987B (zh) * 2020-10-16 2022-04-29 中国农业大学 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
AU7058691A (en) 1989-12-22 1991-07-24 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologically active proteines from borrelia burgdorferi, related test kits and vaccine
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0571538T5 (da) 1991-02-15 2002-03-04 Uab Research Foundation Strukturgen for pneumokokprotein
JPH07501687A (ja) 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
AU2903892A (en) 1991-10-22 1993-05-21 Symbicom Aktiebolag Improvement in (borrelia burgdorferi) diagnosis and prophylaxis
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
CA2196311A1 (en) 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
CN1561389A (zh) 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
DE10164309A1 (de) * 2001-12-28 2003-07-10 Fraunhofer Ges Forschung Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle
CA2494971A1 (en) * 2002-08-14 2004-02-26 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
AU2004311630A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
ES2389080T3 (es) 2004-06-11 2012-10-23 Riken Fármaco que presenta un ligando de células reguladoras contenido en el liposoma
CN1980638B (zh) * 2004-07-07 2011-10-12 国立血清研究所 用糖脂稳定基于脂质的佐剂制剂的组合物和方法
US9079765B2 (en) * 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
AU2006219717B2 (en) * 2005-03-02 2009-05-21 The Secretary Of State For Defence Pharmaceutical composition
EP1945651B1 (en) 2005-10-25 2014-06-25 The Ludwig Institute for Cancer Research Analogs of alpha galactosylceramide and uses thereof
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
JP5721620B2 (ja) * 2008-05-02 2015-05-20 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 免疫応答を刺激するための作製物および方法
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Also Published As

Publication number Publication date
EP2711021A1 (en) 2014-03-26
EP2711020A1 (en) 2014-03-26
CN102170903B (zh) 2016-04-06
EP2711021B1 (en) 2016-03-09
CA2723226A1 (en) 2009-05-11
WO2009133378A3 (en) 2009-12-23
WO2009133378A2 (en) 2009-11-05
JP2011519847A (ja) 2011-07-14
JP2015038066A (ja) 2015-02-26
JP2015028023A (ja) 2015-02-12
US20110280930A1 (en) 2011-11-17
AU2009241645A1 (en) 2009-11-05
HK1190942A1 (en) 2014-07-18
CN102170903A (zh) 2011-08-31
EP2288381A2 (en) 2011-03-02
AU2009241645B2 (en) 2014-07-17
HK1191548A1 (en) 2014-08-01
HK1161542A1 (zh) 2012-07-27
JP5721620B2 (ja) 2015-05-20
JP5853068B2 (ja) 2016-02-09
EP2711020B1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
ES2570973T3 (es) Productos y métodos para la estimulación de una respuesta inmunitaria
AR074501A1 (es) Oligonucleotidos inmunoestimuladores
PL2170584T3 (pl) Sposób naklejania powłoki na zakrzywione podłoże
CR20110087A (es) Metodo y montaje para productos tri-dimencionales
TW200722101A (en) Novel composition
WO2010115122A3 (en) Generation of uniform fragments of nucleic acids using patterned substrates
CR10559A (es) Vacuna de influenza
EP1992479A4 (en) FILM SUBSTRATE OF A PRIMED SEPARATE FOIL, embossed release sheet, method of making a sheet stock from a sewn release sheet, method of making a sewn release sheet, a device for making a sewn release sheet, an artificial leather, and method of making an artificial leather
JP2011519847A5 (https=)
WO2009143457A3 (en) Vaccine composition containing synthetic adjuvant
WO2008127296A3 (en) Methods and compositions for treating tularemia
WO2006020889A3 (en) Dendritic cell vaccines for treating cancer made from embryonic stem cells
AR072151A1 (es) Metodo para producir lentes de contacto de hidrogel de silicona
BR112013014265A8 (pt) sequência de ácido nucleico isolada, receptor antígeno quimérico isolado, célula, vetor, e, métodos para estimular uma resposta imune mediada por célula t, para fornecer uma imunidade antitumoral em um mamífero, para tratar um mamífero tendo uma doença, distúrbio ou condição, para tratar um ser humano com uma doença, para gerar uma população persistente de célula t, e para expandir uma população de célula t
MX2009012991A (es) Metodo para obtener un sustrato texturizado para un panel fotovoltaico.
NZ577405A (en) Vaccines including antigen from four strains of influenza virus
AR042549A1 (es) Un procedimiento para la preparacion de particulas de latex injertadas con polisacaridos
CL2011000914A1 (es) Vacuna combinada estable completamente liquida que comprende antigenos difterico, tetanico, pertusico acelular, de haemophilus influenzae, y de virus de poliomielitis en donde el antigeno se haemophilus influenzae no esta sustancialmente absorbido sobre ningun adyuvante; y proceso de fabricacion.
MX2022010642A (es) Vacunas contra coronavirus que comprenden un agonista de tlr9.
WO2013160252A3 (en) Dry silicone gels and their methods of making using thiol-ene chemistry
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2010044919A3 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
NZ596366A (en) Enhanced immune response in avian species
WO2008010099A3 (en) Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
BRPI0818718B8 (pt) processo de preparo de uma composição de vacina compreendendo antígeno e adjuvante na forma de látex inverso de homopolímero do ácido acrílico